Skip to main content
European Commission logo print header

STOP SPREAD BAD BUGS: novel antimicrobial approaches to combat multidrug resistance in bacteria

Project description

Training network for the development of novel antibiotics to fight antimicrobial resistance

Multidrug resistance in bacteria requires urgent development of alternative approaches to discover novel antibiotics. Funded by the Marie Skłodowska-Curie Actions programme, the STOP SPREAD BAD BUGS project is a research training consortium that will train 15 early stage researchers in drug development, infectiology, immunology and pharmacology. Carried out by experts, the training will cover topics such as carbohydrate and protein chemistry for drug discovery, mechanisms of action of current antimicrobial compounds, and computational chemistry of the interactions of the novel antibiotics with pathogens. A range of infection models and state-of-the-art imaging tools will enable trainees to determine efficacy in preclinical tests and track the bacteria and antibiotics in these test systems.


STOP SPREAD BAD BUGS is a new multi-disciplinary research/training consortium built to combat the alarming problem of global antimicrobial resistance. Multi-drug resistance (MDR) in bacteria is becoming increasingly common thus urgently calling for alternative approaches to develop and implement novel antibiotics. We envision a definitive solution that will require a paradigm shift. Its foundation shall be the training of a new generation of future 15 Early Stage Researchers (ESRs) by world-renowned experts in the field of drug development, infectiology, immunology and pharmacology. A unique state-of the-art teaching/training pipeline shall be developed across 7 academic and 5 SME partners with complementary expertise in the development and testing of novel approaches to antimicrobial therapy in humans. We shall establish knowledge and expertise on carbohydrate and protein chemistry for the discovery of new drug candidates, while characterizing the underlying mechanism of existing compounds for treatment of microbial infections. Computational modelling shall optimize the interactions of the novel entities with selected pathogens. A range of infection models allows partners to simultaneously determine compound efficacy in pre-clinical settings and investigate the potential effects of the novel antimicrobials on host tissues. State-of-the-art imaging tools will be applied to track the bacteria and novel compounds in these test systems. Uniquely, the pipeline will also determine the pharmacokinetics, and the effects of compounds on host microbiota and host immunity. Understanding the mechanisms of action of the novel antimicrobials shall provide insights into new antimicrobial mechanisms, which may be further exploited in spin-off projects. This approach means that the STOP SPREAD BAD BUGS consortium will deliver uniquely trained, multi- and interdisciplinary ESRs that will take the continuing fight against global MDR safely into the future.

Funding Scheme



Net EU contribution
€ 548 740,80
Dr molewaterplein 40
3015 GD Rotterdam

See on map

West-Nederland Zuid-Holland Groot-Rijnmond
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00

Participants (13)

Partners (11)